NASDAQ · Biotechnology

GH Research PLC (GHRS) Stock

$20.45 -2.90% NASDAQ: GHRS Healthcare

Valuation

MetricValue
Price$20.45
Market Cap$1.40B
P/E Ratio-22.71
P/B Ratio4.20
P/S Ratio0.00
EPS (TTM)$-0.79
52-Week High$31.44
52-Week Low$12.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-20.86%
ROA-16.72%
ROCE-19.87%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio35.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-15.0M$-31.0M$-41.0M$-50.0M$-61.0M
Net Profit$-9.0M$-22.0M$-36.0M$-39.0M$-48.0M
EPS$-0.18$-0.14$-0.68$-0.75$-0.79
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$280.0M$254.0M$226.0M$188.0M$288.0M
Total Liabilities$3.0M$5.0M$7.0M$9.0M$9.0M
Cash$277.0M$166.0M$78.0M$101.0M$246.0M
Borrowings$0$0$1.0M$1.0M$1.0M

Latest News

The Race to Commercialize the World’s Most Powerful Psychedelic WSJ · Jul 14, 2026 Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says Proactive · Jul 13, 2026 Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026? Zacks · Jul 2, 2026 AtaiBeckley Reflects a New Push for Rapid-Acting Mental Health Drugs Zacks · Jul 2, 2026 AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026 Zacks · Jul 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-26.0M$-33.0M$-42.0M$-44.0M
Investing Cash Flow$0$-85.0M$-54.0M$65.0M$46.0M
Financing Cash Flow$-23.0M$0$0$0$0
Net Cash Flow$271.0M$-111.0M$-88.0M$22.0M$145.0M
Free Cash Flow$-15.0M$-26.0M$-33.0M$-42.0M$-44.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.79
EV / EBITDA-19.64
FCF Yield-3.37%
Quick Ratio28.70
Interest Coverage-355.41
Return 1Y71.24%
Return 3Y118.17%
Return 5Y65.11%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANROAlto Neuroscience, Inc. $24.03 +2.17% -9.71 $843.31M 0.00%
BHVNBiohaven Ltd. $11.93 +0.42% -2.77 $1.80B 0.00%
DFTXDefinium Therapeutics, Inc. $34.18 -2.59% -10.87 $4.54B 0.00%
LBRXLB Pharmaceuticals Inc $34.61 +1.32% -12.45 $992.50M 0.00%
MPLTMapLight Therapeutics, Inc. $9.15 -2.24% -1.90 $388.29M 0.00%

About GH Research PLC

GH Research PLC is led by CEO Velichka Valcheva, employs 50 people, headquartered in IE, publicly traded since 2021.

GH Research PLC (GHRS) stock trades at $20.45 with a market capitalization of $1.40B. The stock is valued at a price-to-earnings (P/E) ratio of -22.71, price-to-book of 4.20, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.04 and $31.44, and currently trades 35.0% below its 52-week high.

On profitability, GH Research PLC generates a return on equity (ROE) of -20.86%, return on capital employed of -19.87%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides